Skip to main content
OpenTrials
Completed

NCT Number: NCT04836065

ESICM UNITE COVID-19 Project (UNITE-COVID)

COVID-19 is arguably the biggest challenge critical care medicine has been confronted with since its conception. Critical care services around the world are flooded by patients presenting with severe respiratory failure who require prolonged treatment in the ICU. Despite the support provided, outcomes are poor, particularly in ventilated patients.

Many unanswered questions remain regarding the pathophysiology of COVID-19, particularly in severely ill patients. No evidence-based treatment is currently available, yet different often experimental therapies are administered to patients.

As experience grows, new phenotypes are recognized, and unreported complications are observed in the most severely ill patients. Although many registries are currently including patients, few of them focus on ICU patients and their specific treatments and newly observed complications and challenges.

Although the pandemic may appear on its return in many countries that are now easing the restrictions that were put in place to limit the spread of the disease, it can be expected that COVID-19 will be a continued challenge in ICUs globally until a safe and effective vaccine is found. Efforts to study the disease should continue in order to advance our understanding of the disease as well as improve treatment options.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Infection COVID-19 Cardiovascular Diseases Coronaviridae Infections Coronavirus Infections Dyspnea Embolism and Thrombosis Infections Inflammation Lung Diseases Nidovirales Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral RNA Virus Infections Respiration Disorders Respiratory Tract Diseases Respiratory Tract Infections Signs and Symptoms Signs and Symptoms, Respiratory Thromboembolism Thrombosis Vascular Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ghent University Hospital

Ghent, 9000, Belgium

About this study

This is a multicenter, international, anonymized point prevalence study. Patients who were present in the ICU on the day in April 2020 with the highest number of COVID-19 patients in the unit. Data can be entered in the database until July 2020. Retrospective data collection and entry is allowed.

Subjects believed to fulfill all eligibility criteria, and none of the exclusion criteria, detailed in the relevant section of this protocol, will be included in the study.

Data will be entered in the database anonymously.

Data will consist of two core elements:

  • Center data (to be completed once)
  • Patient data

For different domains with specific, highly relevant and un(der)explored ICU research questions, an focused data set is to be completed. These domains include:

  • Respiratory
  • Coagulation and thrombo-embolic events
  • Infectious complications
  • Rehabilitation
  • Renal

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is present in an ICU or in any other place of the hospital under the care of the critical care team on the day between 15th February 2020 and 15th June 2020 with the highest number of COVID-19 patients in the unit. The exact date can be decided by the local investigator.
  • COVID-19 confirmed diagnosis through PCR or equivalent diagnostic technique

Exclusion criteria

  • Any of the following is regarded as a criterion for exclusion from the study: SARS-CoV2 positive without COVID-19

Treatment and study plan

Primary outcomes

  1. Number of patients admitted with confirmed COVID19 infection

    Time frame: One day with 60 day follow-up

    Number of patients in the ICU on the study day

  2. Mortality (ICU)

    Time frame: One day with 60 day follow-up

    Proportion of patients who have died at ICU discharge

  3. Mortality (60-day)

    Time frame: One day with 60 day follow-up

    Proportion of patients who have died at day 60

Secondary outcomes

  1. Duration of hospitalization in the ICU

    Time frame: One day with 60 day follow-up

    Length of stay in the ICU

  2. Proportion of patients requiring invasive mechanical ventilation

    Time frame: One day with 60 day follow-up

    Proportion of patients who require invasive mechanical ventilation during ICU stay versus all patients

  3. Proportion of patients developing infections during ICU stay

    Time frame: One day with 60 day follow-up

    Proportion of patients who acquire an infection during their ICU stay versus all patients

  4. Proportion of patients developing thromboembolic events during ICU stay

    Time frame: One day with 60 day follow-up

    Proportion of patients who develop any thromboembolic event during their ICU stay versus all patients

  5. Proportion of patients requiring tracheotomy during ICU stay

    Time frame: One day with 60 day follow-up

    Proportion of patients who are require a tracheostomy versus all patients

Sponsors and collaborators

Lead sponsor

University Hospital, Ghent

Other

Collaborators

  • European Society of Intensive Care Medicine

Registry information

Official study title

European Society Of Intensive Care Medicine COVID-19 Project (UNITE-COVID)

Acronym: UNITE-COVID

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 8, 2021
Registry last updated
Apr 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.